ai
Anthropic Launches Pre-Clinical Drug Programs for Neglected Diseases and New Claude Science App
The AI company launched Claude Science on June 30 and said it will start its own drug programs. Executives said the effort will give the firm direct experience applying its tools to scientific problems.
StatAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Anthropic announced June 30 that it will begin developing its own pre-clinical drug programs focused on neglected diseases. The company made the announcement during an event in San Francisco where it also launched its new application Claude Science. Stat reported that the programs target conditions the traditional pharmaceutical industry often overlooks.
Eric Kauderer-Abrams, Anthropic’s head of life sciences, said during a press briefing that the diseases carry real burden even if they fall outside typical commercial priorities. Executives told Stat that the company wants hands-on experience using its own products to solve real scientific problems. Jonah Cool leads Anthropic’s life sciences partnerships and deployment.
The event occurred the day before the current reporting date. Anthropic has not stated whether it plans to advance any candidates to commercialization.
Transparency
How sources framed this
These outlets didn't split into competing frames — coverage was uniform.
CorroborationModerate · 2 sources
